The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future

Andrew M. Evens; Martin S. Tallman; Ronald B. Gartenhaus

doi:10.1016/j.leukres.2004.01.011

The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future

Andrew M. Evens, Martin S. Tallman, Ronald B. Gartenhaus^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

152 Scopus citations

Abstract

Arsenic trioxide (As₂O₃) is an effective therapy for acute promyelocytic leukemia (APL), and there has been promising activity noted in other hematologic and solid tumors. The mechanism of action of As ₂O₃ such as differentiation and apoptosis has prompted study into combination therapy. Furthermore, the connection of the sensitivity of diseases such as APL and multiple myeloma to oxidative damage has allowed the investigation of pharmacologic modulation of the cellular redox state for potentiation of As₂O₃. Continued study of As ₂O₃ as a single-agent and in combination therapy will allow identification of the safest and most effective treatment regimens for malignant disease.

Original language	English (US)
Pages (from-to)	891-900
Number of pages	10
Journal	Leukemia Research
Volume	28
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2004.01.011
State	Published - Sep 2004

Keywords

Acute promyelocytic leukemia
Arsenic trioxide
Pharmacologic modulation

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2004.01.011

Cite this

@article{08f14e04c61243e280a473731f38fcf5,

title = "The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future",

abstract = "Arsenic trioxide (As2O3) is an effective therapy for acute promyelocytic leukemia (APL), and there has been promising activity noted in other hematologic and solid tumors. The mechanism of action of As 2O3 such as differentiation and apoptosis has prompted study into combination therapy. Furthermore, the connection of the sensitivity of diseases such as APL and multiple myeloma to oxidative damage has allowed the investigation of pharmacologic modulation of the cellular redox state for potentiation of As2O3. Continued study of As 2O3 as a single-agent and in combination therapy will allow identification of the safest and most effective treatment regimens for malignant disease.",

keywords = "Acute promyelocytic leukemia, Arsenic trioxide, Pharmacologic modulation",

author = "Evens, {Andrew M.} and Tallman, {Martin S.} and Gartenhaus, {Ronald B.}",

year = "2004",

month = sep,

doi = "10.1016/j.leukres.2004.01.011",

language = "English (US)",

volume = "28",

pages = "891--900",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - The potential of arsenic trioxide in the treatment of malignant disease

T2 - Past, present, and future

AU - Evens, Andrew M.

AU - Tallman, Martin S.

AU - Gartenhaus, Ronald B.

PY - 2004/9

Y1 - 2004/9

N2 - Arsenic trioxide (As2O3) is an effective therapy for acute promyelocytic leukemia (APL), and there has been promising activity noted in other hematologic and solid tumors. The mechanism of action of As 2O3 such as differentiation and apoptosis has prompted study into combination therapy. Furthermore, the connection of the sensitivity of diseases such as APL and multiple myeloma to oxidative damage has allowed the investigation of pharmacologic modulation of the cellular redox state for potentiation of As2O3. Continued study of As 2O3 as a single-agent and in combination therapy will allow identification of the safest and most effective treatment regimens for malignant disease.

AB - Arsenic trioxide (As2O3) is an effective therapy for acute promyelocytic leukemia (APL), and there has been promising activity noted in other hematologic and solid tumors. The mechanism of action of As 2O3 such as differentiation and apoptosis has prompted study into combination therapy. Furthermore, the connection of the sensitivity of diseases such as APL and multiple myeloma to oxidative damage has allowed the investigation of pharmacologic modulation of the cellular redox state for potentiation of As2O3. Continued study of As 2O3 as a single-agent and in combination therapy will allow identification of the safest and most effective treatment regimens for malignant disease.

KW - Acute promyelocytic leukemia

KW - Arsenic trioxide

KW - Pharmacologic modulation

UR - http://www.scopus.com/inward/record.url?scp=3242666928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242666928&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2004.01.011

DO - 10.1016/j.leukres.2004.01.011

M3 - Review article

C2 - 15234563

AN - SCOPUS:3242666928

VL - 28

SP - 891

EP - 900

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -

The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this